Pharma Gets Love, Fintech Takes a Hit

Analyst target price revisions dominated Friday's tape. Healthcare names drew the most upgrades while payments tech faced fresh selling pressure.

ABBV led the healthcare moves. Analysts lifted the consensus target to $273.86, up from $273.39. The pharma giant carries a $435 billion market cap and remains lightly shorted at just 1.3% of free float.

AMGN also saw its target nudge higher to $378.31. The biotech's 33-analyst consensus holds 16 holds against 13 sells. Short interest sits at 2.4% of free float.

The day's notable downgrade came at FIS. Analysts cut the consensus target to $51.09 from $52.45. The fintech has 14 sell ratings — more than buys. With $22 billion in market cap, the bearish skew stands out.

FANG — Diamondback Energy — also saw a target trim to $232.75. Oil price headwinds appear to be weighing on analyst conviction in the Permian Basin producer.

On the real estate side, ARE — Alexandria Real Estate Equities — got a target bump to $52.36. The lab-focused REIT has two buy ratings against just two sells.

The broad pattern: defensive healthcare names are earning analyst support. Rate-sensitive and energy plays face more caution heading into the second half.